Brentuximab Vedotin (Adcetris) for Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides - Details


( Last Updated : December 18, 2020)
Generic Name:
Brentuximab Vedotin
Project Status:
Complete
Therapeutic Area:
Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF)
Manufacturer:
Seattle Genetics, Inc.
Brand Name:
Adcetris
Project Line:
Reimbursement Review
Project Number:
PC0213-000
NOC Date:

Details


Strength:
50 mg
Tumour Type:
Lymphoma
Indications:
Primary Cutaneous Anaplastic Large Cell Lymphoma or CD30-Expressing Mycosis Fungoides
Funding Request:
For the treatment of adult patients with pcALCL or CD30-expressing MF who have had prior systemic therapy.
Review Status:
Complete
Sponsor:
Seattle Genetics, Inc.
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Funding Request:
For the treatment of adult patients with pcALCL or CD30-expressing MF who have had prior systemic therapy.
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.